US FDA staff raise no major concerns about Eli Lilly Alzheimer's drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Eli Lilly (LLY) PT Raised to $957 at Jefferies
June 6, 2024 4:27 PM EDTJefferies analyst Akash Tewari raised the price target on Eli Lilly (NYSE: LLY) to $957.00 (from $925.00) while maintaining a Buy rating.
The analyst comments "Dona's Ad Com documents look fine we note 1) FDA didn't agree w/ LLY on changing primary endpoint but believes data supports... More
